2Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin-United States.MorbI.Mortal.. Wkly.Rep. 1997; 46:624-626
3Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States.Morbl. Mortal.. Wkly. Rep. 1997; 46:813-815
4Smith TL, Pearson ML, Wilcox KR Cruz C, Lancaster MV,Robinson-dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR. Emergence of vancomycin resistance in Staphylococcus aureus.N.Eng J.Med 1999; 340:493-501
5Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med.1999; 340:517-523
6Geisel R, Schmitz F J, Thomas L, Berns G, Zetsche O, Ulrich B, FluitAC, Labischiusky H, Witte W. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J. Antimicrob. Chemother. 1999; 43:846-848
7Marlowe EM, Cohen MD, Hindler JF, Ward KW, Bruckner DA.Practical strategies for detecting and confirming vancomycin-intermediate Staphylococcus aureus: a tertiary-carc hospital laboratory's experience. J. Clin. Microbiol. 2001, 39:2637-2639
8Ploy MC, Grelaud C, Martin C, Lumley LD, Denis F. First Clinic Isolates of vancomycin-intermediate Staphylococcus aureus in a French Hospital. Lancet. 1998; 3511212-3511213
9Ariza J, Pujol M, Cabo J, Pena C, Fernandez N; Linares J, Ayats J,Gudiol F. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet. 1999; 353:1587-1588
10Kantzanou M, Tassios PT, Tseleni-Kotsovili A, Legakis NJ Vatopoulos AC. Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus. J. Antimicrob.Chemther. 1999; 43:729-731
